253 related articles for article (PubMed ID: 28848438)
41. Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver.
Canivenc-Lavier MC; Vernevaut MF; Totis M; Siess MH; Magdalou J; Suschetet M
Toxicology; 1996 Nov; 114(1):19-27. PubMed ID: 8931757
[TBL] [Abstract][Full Text] [Related]
42. Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.
Miyauchi E; Tachikawa M; Declèves X; Uchida Y; Bouillot JL; Poitou C; Oppert JM; Mouly S; Bergmann JF; Terasaki T; Scherrmann JM; Lloret-Linares C
Mol Pharm; 2016 Aug; 13(8):2631-40. PubMed ID: 27347605
[TBL] [Abstract][Full Text] [Related]
43. Regulation of Mammalian UDP-Glucuronosyltransferases.
Wang H; Cao G; Wang G; Hao H
Curr Drug Metab; 2018; 19(6):490-501. PubMed ID: 29521218
[TBL] [Abstract][Full Text] [Related]
44. The catalytic function of cytochrome P450 is entwined with its membrane-bound nature.
Barnaba C; Gentry K; Sumangala N; Ramamoorthy A
F1000Res; 2017; 6():662. PubMed ID: 28529725
[TBL] [Abstract][Full Text] [Related]
45. Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance?
Chen F; Li DY; Zhang B; Sun JY; Sun F; Ji X; Qiu JC; Parker RB; Laizure SC; Xu J
Drug Metab Rev; 2018 Aug; 50(3):369-397. PubMed ID: 30221555
[TBL] [Abstract][Full Text] [Related]
46. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
47. Current views on the fundamental mechanisms of cytochrome P450 allosterism.
Atkins WM
Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):573-9. PubMed ID: 16859405
[TBL] [Abstract][Full Text] [Related]
48. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Locuson CW; Wienkers LC; Jones JP; Tracy TS
Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
[TBL] [Abstract][Full Text] [Related]
49. High levels of autoantibodies against drug-metabolizing enzymes in SLA/LP-positive AIH-1 sera.
Shinoda M; Tanaka Y; Kuno T; Matsufuji T; Matsufuji S; Murakami Y; Mizutani T
Autoimmunity; 2004; 37(6-7):473-80. PubMed ID: 15621574
[TBL] [Abstract][Full Text] [Related]
50. Interactions of drug-metabolizing enzymes with the Chinese herb Psoraleae Fructus.
Zhou QH; Zhu YD; Zhang F; Song YQ; Jia SN; Zhu L; Fang SQ; Ge GB
Chin J Nat Med; 2019 Nov; 17(11):858-870. PubMed ID: 31831132
[TBL] [Abstract][Full Text] [Related]
51. Regulation of phase II biotransformation enzymes by steroid hormones.
Kohalmy K; Vrzal R
Curr Drug Metab; 2011 Feb; 12(2):104-23. PubMed ID: 21401512
[TBL] [Abstract][Full Text] [Related]
52. The inhibitory effects of β-caryophyllene, β-caryophyllene oxide and α-humulene on the activities of the main drug-metabolizing enzymes in rat and human liver in vitro.
Nguyen LT; Myslivečková Z; Szotáková B; Špičáková A; Lněničková K; Ambrož M; Kubíček V; Krasulová K; Anzenbacher P; Skálová L
Chem Biol Interact; 2017 Dec; 278():123-128. PubMed ID: 29074051
[TBL] [Abstract][Full Text] [Related]
53. Flavonoids as modulators of metabolic enzymes and drug transporters.
Miron A; Aprotosoaie AC; Trifan A; Xiao J
Ann N Y Acad Sci; 2017 Jun; 1398(1):152-167. PubMed ID: 28632894
[TBL] [Abstract][Full Text] [Related]
54. Drug metabolizing enzymes and their inhibitors' role in cancer resistance.
Pathania S; Bhatia R; Baldi A; Singh R; Rawal RK
Biomed Pharmacother; 2018 Sep; 105():53-65. PubMed ID: 29843045
[TBL] [Abstract][Full Text] [Related]
55. Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex.
Ishii Y; Iwanaga M; Nishimura Y; Takeda S; Ikushiro S; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H
Drug Metab Pharmacokinet; 2007 Oct; 22(5):367-76. PubMed ID: 17965520
[TBL] [Abstract][Full Text] [Related]
56. Changes in the expression of cytochrome P450 2E1 and the activity of carcinogen-metabolizing enzymes in Schistosoma haematobium-infected human bladder tissues.
Sheweita SA; Abu El-Maati MR; El-Shahat FG; Bazeed MA
Toxicology; 2001 Apr; 162(1):43-52. PubMed ID: 11311457
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of UDP-glucuronosyltransferases (UGTs) by bromophenols (BPs).
Wang F; Wang S; Yang K; Liu YZ; Yang K; Chen Y; Fang ZZ
Chemosphere; 2020 Jan; 238():124645. PubMed ID: 31472352
[TBL] [Abstract][Full Text] [Related]
58. Comparative gene expression of intestinal metabolizing enzymes.
Shin HC; Kim HR; Cho HJ; Yi H; Cho SM; Lee DG; Abd El-Aty AM; Kim JS; Sun D; Amidon GL
Biopharm Drug Dispos; 2009 Nov; 30(8):411-21. PubMed ID: 19746353
[TBL] [Abstract][Full Text] [Related]
59. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
60. SPR-Based study of affinity of cytochrome P450s / redox partners interactions modulated by steroidal substrates.
Ershov PV; Yablokov ЕO; Florinskaya AV; Mezentsev YV; Kaluzhskiy LА; Tumilovich AM; Gilep АА; Usanov SA; Ivanov АS
J Steroid Biochem Mol Biol; 2019 Mar; 187():124-129. PubMed ID: 30468857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
